Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) was the target of a large growth in short interest in the month of December. As ...
Shares of Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight ...
Investing.com - Homology Medicines (NASDAQ: FIXX) reported first quarter EPS of $-0.600, $0.11 worse than the analyst estimate of $-0.492. Revenue for the quarter ...
Q32 Bio, Inc. (NASDAQ:QTTB), a biotechnology company focused on developing therapies for inflammatory diseases, has recently experienced significant shifts in its market outlook following ...
Q32 Bio, Inc. (NASDAQ:QTTB), a biotechnology company focused on developing therapies for inflammatory diseases, has recently experienced significant shifts in its market outlook following ...
Wells Fargo has recently reduced Q32 Bio Inc (QTTB) stock to Equal Weight rating, as announced on December 11, 2024, according to Finviz. Earlier, on December 11, 2024, Raymond James had reduced the ...
Hosted on MSN23d
Guggenheim Downgrades Q32 Bio (QTTB)Fintel reports that on December 12, 2024, Guggenheim downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Buy to Neutral. Analyst Price Forecast Suggests 1,981.80% Upside As of December 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback